AP1M2 and invasive breast carcinoma: Bioinformatic analyses on AP1M2 are not conclusive, e.g., its level has no effect on patient survival in pancreatic cancer [21], it was identified as a hub gene in renal cancer in which its expression is downregulated [22], while its high expression predicted poor outcome in invasive breast carcinoma [23].